Matches in SemOpenAlex for { <https://semopenalex.org/work/W4244282634> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W4244282634 endingPage "28" @default.
- W4244282634 startingPage "25" @default.
- W4244282634 abstract "The proteasome plays a central role in the regulation of many processes critical to solid tumour growth. Proteasome inhibition activates multiple mechanisms capable of arresting tumour proliferation, tumour metastasis, and angiogenesis. In preclinical testing, the novel proteasome inhibitor bortezomib displays a unique pattern of cytotoxicity against a broad spectrum of tumour cell lines. In experimental models of breast, lung, colon, prostate, pancreatic, and ovarian cancer, bortezomib shows additive or synergistic activity when combined with chemotherapeutic agents such as irinotecan, gemcitabine, 5-fluorouracil, cisplatin, paclitaxel, docetaxel, and doxorubicin. Bortezomib is currently being investigated both as a single agent and in combination regimens for the treatment of a broad range of solid tumours including non-small cell lung cancer (NSCLC), renal cell, breast, ovarian, prostate, colon, gastric, and pancreatic cancer. In an ongoing, single-agent phase II trial in NSCLC, one partial response and six instances of stable disease were documented in 15 evaluable patients. Pharmacodynamic studies showed inhibition of NF-κB. Two single-institution phase II trials in renal cell cancer showed four partial responses in 37 patients and one partial response in 21 patients, respectively. Randomised phase II trials of bortezomib with or without docetaxel in patients with NSCLC and with or without irinotecan in patients with colon cancer are ongoing, as are single-agent phase II studies in colon, breast, and ovarian cancer. Bortezomib is also being studied in combination with irinotecan in patients with gastro-oesophageal cancer, with gemcitabine in patients with pancreatic cancer, and with docetaxel in patients with breast and prostate cancer." @default.
- W4244282634 created "2022-05-12" @default.
- W4244282634 creator A5057555103 @default.
- W4244282634 date "2004-06-01" @default.
- W4244282634 modified "2023-10-18" @default.
- W4244282634 title "Clinical potential of proteasome inhibition in solid tumours*1" @default.
- W4244282634 doi "https://doi.org/10.1016/s1359-6349(04)00050-3" @default.
- W4244282634 hasPublicationYear "2004" @default.
- W4244282634 type Work @default.
- W4244282634 citedByCount "0" @default.
- W4244282634 crossrefType "journal-article" @default.
- W4244282634 hasAuthorship W4244282634A5057555103 @default.
- W4244282634 hasConcept C121608353 @default.
- W4244282634 hasConcept C126322002 @default.
- W4244282634 hasConcept C143998085 @default.
- W4244282634 hasConcept C2776364478 @default.
- W4244282634 hasConcept C2777478702 @default.
- W4244282634 hasConcept C2778367456 @default.
- W4244282634 hasConcept C2780192828 @default.
- W4244282634 hasConcept C2780210213 @default.
- W4244282634 hasConcept C2780258809 @default.
- W4244282634 hasConcept C2780259306 @default.
- W4244282634 hasConcept C2780427987 @default.
- W4244282634 hasConcept C2781190966 @default.
- W4244282634 hasConcept C502942594 @default.
- W4244282634 hasConcept C526805850 @default.
- W4244282634 hasConcept C530470458 @default.
- W4244282634 hasConcept C71924100 @default.
- W4244282634 hasConceptScore W4244282634C121608353 @default.
- W4244282634 hasConceptScore W4244282634C126322002 @default.
- W4244282634 hasConceptScore W4244282634C143998085 @default.
- W4244282634 hasConceptScore W4244282634C2776364478 @default.
- W4244282634 hasConceptScore W4244282634C2777478702 @default.
- W4244282634 hasConceptScore W4244282634C2778367456 @default.
- W4244282634 hasConceptScore W4244282634C2780192828 @default.
- W4244282634 hasConceptScore W4244282634C2780210213 @default.
- W4244282634 hasConceptScore W4244282634C2780258809 @default.
- W4244282634 hasConceptScore W4244282634C2780259306 @default.
- W4244282634 hasConceptScore W4244282634C2780427987 @default.
- W4244282634 hasConceptScore W4244282634C2781190966 @default.
- W4244282634 hasConceptScore W4244282634C502942594 @default.
- W4244282634 hasConceptScore W4244282634C526805850 @default.
- W4244282634 hasConceptScore W4244282634C530470458 @default.
- W4244282634 hasConceptScore W4244282634C71924100 @default.
- W4244282634 hasIssue "6" @default.
- W4244282634 hasLocation W42442826341 @default.
- W4244282634 hasOpenAccess W4244282634 @default.
- W4244282634 hasPrimaryLocation W42442826341 @default.
- W4244282634 hasRelatedWork W1970564121 @default.
- W4244282634 hasRelatedWork W1988326884 @default.
- W4244282634 hasRelatedWork W1996983877 @default.
- W4244282634 hasRelatedWork W2007868229 @default.
- W4244282634 hasRelatedWork W2023424949 @default.
- W4244282634 hasRelatedWork W2065498827 @default.
- W4244282634 hasRelatedWork W2098990722 @default.
- W4244282634 hasRelatedWork W2477222816 @default.
- W4244282634 hasRelatedWork W2492342176 @default.
- W4244282634 hasRelatedWork W2971790065 @default.
- W4244282634 hasVolume "2" @default.
- W4244282634 isParatext "false" @default.
- W4244282634 isRetracted "false" @default.
- W4244282634 workType "article" @default.